<SEC-DOCUMENT>0001279569-19-001574.txt : 20190725
<SEC-HEADER>0001279569-19-001574.hdr.sgml : 20190725
<ACCEPTANCE-DATETIME>20190724175558
ACCESSION NUMBER:		0001279569-19-001574
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190724
FILED AS OF DATE:		20190725
DATE AS OF CHANGE:		20190724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AURORA CANNABIS INC
		CENTRAL INDEX KEY:			0001683541
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38691
		FILM NUMBER:		19971929

	BUSINESS ADDRESS:	
		STREET 1:		500 - 10355 JASPER AVENUE
		CITY:			EDMONTON
		STATE:			A0
		ZIP:			T5J 1Y6
		BUSINESS PHONE:		604-362-5207

	MAIL ADDRESS:	
		STREET 1:		900 - 510 SEYMOUR STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6B 1V5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aurora_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B>RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of <B>July 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File No. <B>001-38691</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>AURORA
CANNABIS INC.</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"></FONT><BR>
<FONT STYLE="font-size: 10pt">(Translation of registrant's name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>500 - 10355 Jasper Avenue</B><BR>
<B>Edmonton, Alberta, T5J 1Y6, Canada</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B></B><BR>
(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B> Form
40-F&nbsp;&nbsp;&#9746;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>SUBMITTED HEREWITH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font: 12pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD>
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="width: 90%; font: 12pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; text-align: left; text-transform: uppercase"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">News
Release dated July 24, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></A></TD>
    <TD></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm"></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>AURORA CANNABIS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">/s/ <I>Glen Ibbott</I></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><I></I><BR>
Glen Ibbott<BR>
Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Date:  July 24, 2019</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 24, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.jpg" ALT="Aurora Cannabis Inc. (CNW Group|Aurora Cannabis Inc.)" STYLE="height: 300px; width: 400px"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora Cannabis and UFC&reg; Launch Clinical
Research on Use of Hemp-Derived CBD Products by MMA Athletes</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; text-align: center; margin-right: 0; margin-left: 0"><B><I>New studies to advance
the science on CBD use and athlete health and wellness and to drive product development under new U.S. sports performance brand,
ROAR Sports</I></B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">TSX: ACB | NYSE: ACB&nbsp;&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">LAS VEGAS, July 24, 2019 /CNW/ - Aurora Cannabis
Inc. (&quot;Aurora&quot; or the &quot;Company&quot;) (NYSE: ACB) (TSX: ACB), the Canadian company that's defining the future of
cannabis worldwide, and UFC, the world's premier mixed martial arts organization, are proud to announce the launch of a joint clinical
research program that will produce multiple studies under the terms of their recently announced partnership.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The research will examine the use of hemp-derived
CBD as an effective treatment for pain, inflammation, wound-healing, and recovery on MMA athletes.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The ground-breaking research partnership is
aimed at understanding key health and recovery needs of elite athletes in such a highly physical and competitive sport as mixed
martial arts. Research data will then be used to drive the development of science-backed, hemp-derived CBD topicals that will be
safe and reliable. These new products will help combat the rapidly growing market of untested CBD treatments currently being used
by high-performance and non-professional athletes.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Once research is complete, any resulting product
will come to life in the U.S. under the new high-performance sports brand ROAR Sports, a portfolio of high-quality, hemp-derived
CBD topical treatments scientifically formulated with elite athletes in mind. Through analysis of athlete needs and scientific
data, ROAR Sports will challenge the status quo, seek&nbsp;to alleviate the stresses of competition, and earn designation as the
&quot;Official CBD product of UFC.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The multi-phase clinical study at the UFC Performance
Institute<SUP>&reg;</SUP>&nbsp;in Las Vegas will be led by Dr. Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee;
Dr. Kelly Narine, Aurora's Vice President Global Research and Medical Affairs; and the team of sports performance experts at the
UFC Performance Institute, led by Dr. Duncan French, UFC Vice President of Performance. Using active UFC athletes on a strictly
voluntary basis, the study will help&nbsp;establish peer-reviewed, publishable research in this area. Products will be developed
in full compliance with U.S. federal law and with UFC's anti-doping program, which adheres to WADA and USADA regulations.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Our partnership with UFC is about committing
to the science that will educate and advocate,&quot; said Aurora CEO Terry Booth. &quot;We are going to work together to change
the way people think, to change the industry, and to launch the first hemp-derived CBD products that are backed by scientific research.
The brand-building and product development are all part of our move into the U.S., and in collaboration with UFC, and we intend
to play a major role in that market.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;We know anecdotally that professional
athletes across sports disciplines are turning to hemp-derived CBD treatments to assist with physical recovery, with varying degrees
of success,&quot; added Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee. &quot;The work we do in partnership
with UFC will create an evidence-based, science-backed pipeline of consistent, and 'clean' hemp-derived CBD topicals that the high-performance
athletes of UFC can rely on to treat the pain, inflammation, injury and other conditions associated with competing at such a high
level.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Collaborating with Aurora is the best
way to educate ourselves and our fighters about the impact of CBD on MMA athletes and our sport,&quot; said Dr. Duncan French,
UFC's Vice President of Performance. &quot;We want to apply science and see where it leads us.&nbsp; Ideally, these studies will
give us the clarity we need to determine n the effectiveness of hemp-derived CBD on athlete health and injury recovery.&quot; &nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Although CBD is allowed under USADA and
WADA regulations, we want to be the leaders on educating UFC athletes on CBD use,&quot; said Jeff Novitzky, UFC Senior Vice President
of Athlete Health &amp; Performance.&nbsp; &quot;Athlete safety is a top priority for UFC, and we will collaborate with Aurora
to ensure that any new products are third-party tested for all WADA-prohibited substances to make certain they meet WADA standards.&quot;&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><I>Download the media kit HERE.</I></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About UFC&reg;</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">UFC&reg;, is the world's premier mixed martial
arts organization and the largest Pay-Per-View event provider in the world. UFC boasts more than 300 million fans worldwide, including
70 million social media followers across all its digital platforms, and its programming is broadcast in over 170 countries and
territories to one billion TV households worldwide in 40 different languages. UFC produces more than 40 live events annually and
consistently sells out some of the world's most prestigious arenas. Since 2001, UFC has been proudly headquartered in Las Vegas,
supported by a network of employees around the world. UFC's current roster of athletes features more than 590 men and women representing
over 60 countries. UFC FIGHT PASS&reg;, the world's leading digital subscription service for combat sports, delivers exclusive
live events, thousands of fights on-demand, and original content to fans around the world. UFC was acquired in 2016 by global sports,
entertainment, and fashion leader Endeavor, along with strategic investors Silver Lake Partners and KKR, in what is among the largest
transactions in sports history. For more information, visit UFC.com and follow UFC at Facebook.com/UFC, Twitter, Snapchat and Instagram:
@UFC.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Aurora&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Headquartered in Edmonton, Alberta, Canada
with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora
is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across
every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis
and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are
designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards. EU GMP certification has been granted to Aurora's first production
facility in Mountain View County, the Aurora River facility in Bradford, Ontario, and its wholly owned European medical cannabis
distributor Aurora Deutschland.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In addition to the Company's rapid organic
growth and strong execution on strategic M&amp;A, which to date includes 15 wholly owned subsidiary companies &ndash; MedReleaf,
CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,
CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, and Chemi Pharmaceutical
&ndash; Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested
in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI),
Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings
Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH),
Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI) and EnWave Corporation (TSXV: ENW).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora's Common Shares trade on the TSX and
NYSE under the symbol &quot;ACB&quot;, and are a constituent of the S&amp;P/TSX Composite Index.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For more information about Aurora, please visit
our investor website, investor.auroramj.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Terry Booth, CEO<BR>
Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward looking statements</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This news release includes statements containing
certain &quot;forward-looking information&quot; within the meaning of applicable securities law (&quot;forward-looking statements&quot;),
including, but not limited to, statements with respect to the performance of the Company. Forward-looking statements are frequently
characterized by words such as &quot;plan&quot;, &quot;continue&quot;, &quot;expect&quot;, &quot;project&quot;, &quot;intend&quot;,
&quot;believe&quot;, &quot;anticipate&quot;, &quot;estimate&quot;, &quot;may&quot;, &quot;will&quot;, &quot;potential&quot;, &quot;proposed&quot;
and other similar words, or statements that certain events or conditions &quot;may&quot; or &quot;will&quot; occur, and include,
but are not limited to,&nbsp; the successful completion of the&nbsp; clinical research program and the development and commercialization
of&nbsp; hemp- derived CBD topical products . These statements are only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking
statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety
of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected
in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as
expressly required by applicable law.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Neither TSX, NYSE nor their applicable Regulation
Services Providers (as that term is defined in the policies of the Toronto Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.gif" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-and-ufc-launch-clinical-research-on-use-of-hemp-derived-cbd-products-by-mma-athletes-300890611.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/July2019/24/c6010.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001683541</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Aurora Media: Heather MacGregor,
+1.416.509.5416, heather.macgregor@auroramj.com; Aurora Investors: Rob Kelly, +1.647.331.7228, rob.kelly@auroramj.com; UFC: Chris
Bellitti, +1.702.956.6575, chris.bellitti@ufc.com; U.S. Investors, Phil Carlson / Elizabeth Barker, KCSA Strategic Communications,
Phone: (212) 896-1233 / (212) 896-1203, Email: pcarlson@kcsa.com / ebarker@kcsa.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 17:15e 24-JUL-19</P>



<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A#  , '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[0'D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4E2AP? '%#1187%R<[$S0Q4B,C5$\6+2(T+A_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
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MEP2GRTJ73147J4D_.)<]^_?Q/T*X7A%J  #Z
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M;"W922HF621^_K<Y=ZJ9@!XJJJM5.QC&L:C6I@@ !\/T
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MLT3<9J]0!J%_Z8:?02_<;=::B?\ IAI]!+]QMUI)VE^S]#?$K]@?Y7WG^!(
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M$ D$9IQ&:<0"01FG$9IQ )!&:<1FG$ D$9IQ&:<0"01FG$9IQ )!&:<1FG$
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M\/O@ J)I0
M
M
M
M
M
2                    !__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
